Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment?

Authors

  • J. Fichna,

    1. Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
    2. Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, AB, Canada
    3. Department of Biomolecular Chemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
    Search for more papers by this author
  • A. Mokrowiecka,

    1. Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
    Search for more papers by this author
  • A. I. Cygankiewicz,

    1. Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
    Search for more papers by this author
  • P. K. Zakrzewski,

    1. Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
    Search for more papers by this author
  • E. Małecka-Panas,

    1. Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
    Search for more papers by this author
  • A. Janecka,

    1. Department of Biomolecular Chemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
    Search for more papers by this author
  • W. M. Krajewska,

    1. Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
    Search for more papers by this author
  • M. A. Storr

    1. Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
    2. Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, AB, Canada
    3. Department of Medicine, Division of Gastroenterology, Ludwig Maximilians University of Munich, Munich, Germany
    Search for more papers by this author

Address for Correspondence
Martin A. Storr, Division of Gastroenterology, Department of Medicine, Ludwig Maximilians University of Munich, Marchioninistrasse 15, 81377 Munich, Germany.
Tel: ++49 89 7095 0; fax: ++49 3212 1027208; e-mail: gidoc@gmx.com

Abstract

Recent reports suggested that the activation of Transient Receptor Potential Vanilloid 4 (TRPV4) receptors in the gastrointestinal tract has pro-inflammatory effects. In this study, we demonstrated for the first time that TRPV4 mRNA expression is up-regulated in patients with inflammatory bowel diseases (IBD). Furthermore, selective blockade of TRPV4 in the 2,4,6-trinitrobenzenesulfonic acid animal model alleviates colitis and pain associated with the intestinal inflammation. Our study indicates that TRPV4 may play a role in mechanisms of defense in intestinal inflammation and that TRPV4 may be an attractive target for future systemic or topic anti-inflammatory treatment in patients with IBD.

Ancillary